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Abstract The quantitative effects of an Asp79Asn mutation in
the porcine K2A-adrenoceptor on adrenaline-mediated stimula-
tion of the K subunit of individual members of the Gi family of G
proteins were assessed by measuring GTP turnover number for
fusion proteins between the wild type or mutated receptor and
pertussis toxin-resistant forms of each of Gi1, Gi2 and Gi3. In
each case the receptor mutation limited activation of the G
protein to 8^14% of that produced by the wild type receptor.
Previous demonstration that in a single cell this mutation
selectively interferes with K2A-adrenoceptor regulation of distinct
effector end points transduced by Gi family members must
therefore reflect differential requirements for amplification or the
cellular location of individual, co-expressed, G proteins.
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1. Introduction
The K2A-adrenoceptor is one of the most studied members
of the G protein-coupled receptor (GPCR) superfamily which
interact preferentially with pertussis toxin-sensitive, Gi-like,
heterotrimeric G proteins. This receptor can regulate a wide
range of e¡ector end points via interaction with these G pro-
teins including inhibition of adenylyl cyclase [1,2], stimulation
of phospholipase D [3], stimulation of ERK mitogen-activated
protein activity [4,5], stimulation of K currents [2] and in-
hibition of Ca2 currents [2]. Furthermore, at least with high
receptor expression levels and high receptor occupancy, e¡ec-
tor regulation via activation of other G proteins can also be
uncovered [6,7].
Interaction of the K2A-adrenoceptor with the full range of
pertussis toxin-sensitive Gi family G proteins has been re-
corded and studied both in liposome reconstitution experi-
ments [8] and following co-transfection of the receptor and
appropriate G proteins into mammalian cells [9]. Importantly,
both K2A-adrenoceptor-mediated activation of multiple Gi iso-
forms [1,10] and regulation of multiple e¡ectors by these G
proteins [2,3] have been recorded concurrently in individual
cells.
The Asp residue at position 79 of the K2A-adrenoceptor,
which lies in transmembrane region 2, is the most conserved
amino acid in this membrane spanning domain in class I
GPCRs and thus in the nomenclature of van Rhee and Ja-
cobson [11] is denoted 2.50. This amino acid is important for
allosteric regulation by Na of this [12,13] and other GPCRs.
Mutation of this residue to Asn has been shown to result in
elimination of agonist-mediated regulation of K currents but
not of inhibition of adenylyl cyclase or Ca2 currents when
the modi¢ed receptor was expressed in AtT20 anterior pitui-
tary cells [2,14]. A possible explanation for these ¢ndings was
that the mutation selectively interferes with the activation of
one speci¢c Gi family G protein. Alternatively, the mutation
may reduce the capacity of the receptor to activate all G
proteins but the relative expression levels of individual G pro-
teins in cells then determine whether e¡ector regulation can
still be recorded [7]. These possibilities have not previously
been addressed experimentally.
Herein we use a strategy in which fusion proteins between
either the wild type or a Asp79Asn mutant of the porcine K2A-
adrenoceptor and pertussis toxin-insensitive forms of each of
Gi1K, Gi2K and Gi3K allow direct measurement of receptor
activation of the G proteins in circumstances in which the
molar ratio and proximity of receptor and G protein are iden-
tical. We demonstrate that the mutation non-selectively mod-
ulates the capacity of the receptor to activate these closely
related G proteins with an 85^90% reduction in the capacity
of adrenaline to stimulate each G protein.
2. Materials and methods
2.1. Materials
All materials for tissue culture were supplied by Life Technologies,
Inc. (Paisley, Strathclyde, UK). [3H]RS-79948-197 (90 Ci/mmol) was
purchased from Amersham Pharmacia Biotech (Amersham, Bucking-
hamshire, UK). Q[32P]GTP (30 Ci/mmol) was obtained from DuPont-
New England Nuclear (Boston, MA, USA). Pertussis toxin (240 Wg/
ml) and all other basic chemicals were purchased from Sigma (Poole,
Dorset, UK) or Boehringer-Mannheim (Mannheim, Germany) and
were of the highest purity available.
2.2. Construction of the K2A-adrenoceptor^G protein fusion proteins
The porcine K2A-adrenoceptor [15] and the Asp79Asn mutant of this
receptor [12] were obtained from Dr L.E. Limbird, Vanderbilt Uni-
versity, Nashville, TN, USA. A Cys351Gly mutant of rat Gi1K was
linked to the wild type K2A-adrenoceptor as described previously to
generate K2A-adrenoceptor^Gly351Gi1K [16] and ligated into the KpnI
and EcoRI sites of the eukaryotic expression vector pcDNA3 (InVi-
trogen, San Diego, CA, USA). Arg351, Ser351, Val351, Phe351, Leu351
and Ile351 rat Gi1K cDNAs in pcDNA3 [17] were digested with the
restriction enzymes SacII and EcoRI. The 0.7 kb fragments so pro-
duced were recovered and ligated with K2A-adrenoceptor^Gly351Gi1K
in pCDNA3 from which the equivalent 1.3 kb SacII-EcoRI fragment
had been removed. This resulted in generation of a series of K2A-
adrenoceptor^Xaa351Gi1K fusion proteins in pcDNA3. Equivalent
strategies were used to generate K2A-adrenoceptor^Ile352Gi2K, K2A-
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adrenoceptor^Ile351Gi3K and the Asp79Asn K2A-adrenoceptor^
Ile351Gi1K, ^Ile352Gi2K and ^Ile351Gi3K fusion constructs.
2.3. Cell culture and transfection
COS-7 cells were maintained in DMEM containing 10% (v/v) new-
born calf serum, 2 mM L-glutamine. Cells were seeded in 100 mm
culture dishes and grown to 60^80% con£uency (18^24 h) prior to
transfection with pcDNA3 containing the relevant cDNA species us-
ing lipofectamine reagent (Life Technologies, Inc.) [16]. For transfec-
tion, 5 Wg of DNA was mixed with 20 Wl of lipofectamine in 1.2 ml of
Opti-MEM (Life Technologies, Inc.) and incubated at room temper-
ature for 30 min prior to the addition of 4.8 ml of Opti-MEM. COS-7
cells were exposed to the DNA/lipofectamine mixture for 5 h. 6 ml of
20% (v/v) newborn calf serum in DMEM was then added to the cells.
Cells were harvested 48 h after transfection. Cells were treated for the
¢nal 24 h prior to cell harvest with pertussis toxin (50 ng/ml).
2.4. Preparation of membranes
Plasma membrane-containing P2 particulate fractions were pre-
pared from cell pastes that had been stored at 380‡C following har-
vest as described previously [18].
2.5. [3H]RS-79948-197 binding studies
Binding assays were initiated by the addition of 5 Wg of protein to
an assay bu¡er (75 mM Tris^HCl, 5 mM EDTA, 12.5 mM MgCl2,
pH 7.5) containing [3H]RS-79948-197 [9,16,19] (0^1 nM). Non-speci¢c
binding was determined in the presence of 100 WM idazoxan. Reac-
tions were incubated at 30‡C for 45 min, and bound ligand was
separated from free by vacuum ¢ltration through GF/C ¢lters. The
¢lters were washed with 3U5 ml of assay bu¡er, and bound ligand
was estimated by liquid scintillation spectrometry.
2.6. High a⁄nity GTPase assays
These were performed as described in [16,20,21]. Non-speci¢c
GTPase was assessed by parallel assays containing 100 WM GTP.
All experiments were performed at least three times on membranes
prepared from individual cell transfections.
3. Results
In previous experiments using fusion proteins between the
porcine K2A-adrenoceptor and the K subunit of Gi1 the con-
struct was rendered insensitive to the ADP-ribosyltransferase
activity of pertussis toxin by replacement of the acceptor
Cys351 of the G protein with Gly [16,20]. This was designed
to ensure that following pertussis toxin treatment of cells ag-
onist stimulation of high a⁄nity GTPase activity must re£ect
activation of the receptor-linked G protein. However, follow-
ing introduction of an Asp79Asn mutation into the K2A-adre-
noceptor within this pertussis toxin-resistant fusion protein
the capacity of adrenaline to stimulate GTPase activity of
the fusion protein was su⁄ciently poor to make detailed anal-
ysis of the e¡ect of the Asp79Asn mutation di⁄cult to quan-
titate (data not shown).
In co-transfection experiments utilising the porcine K2A-
adrenoceptor and forms of Gi1K in which Cys351 was replaced
by each of the other naturally occurring amino acids
Gly351Gi1K was relatively poorly activated by agonists at
this receptor. By contrast, the presence of a highly hydropho-
bic amino acid at this position allowed even greater activation
than the wild type sequence [17]. We therefore constructed
fusion proteins between the wild type porcine K2A-adrenocep-
tor and a number of residue351-substituted (Arg, Gly, Ser, Val,
Phe and Ile) forms of Gi1K. Each of these fusion constructs
was expressed transiently in COS-7 cells which were subse-
quently treated with pertussis toxin. Membrane fractions
were prepared and levels of expression of the constructs re-
corded in each separate transfection by the speci¢c binding of
the high a⁄nity K2A-adrenoceptor antagonist [3H]RS-79948-
197. Basal high a⁄nity GTPase activity and its stimulation by
Fig. 1. The identity of residue 351 of Gi1K determines adrenaline-
stimulated GTPase turnover number of K2A-adrenoceptor^Gi1K fu-
sion proteins. K2A-Adrenoceptor^Gi1K fusion proteins in which resi-
due 351 of the G protein was either Arg, Gly, Ser, Val, Phe or Ile
were expressed transiently in COS-7 cells. Membranes from these
transfected cells were used to measure the levels of expression of
each construct and the capacity of adrenaline (100 WM) to stimulate
high a⁄nity GTPase activity. Extrapolation of the stimulated activ-
ity to Vmax allowed calculation of adrenaline-stimulated GTP turn-
over number (min31) for each fusion construct. Results are the
means of at least three experiments performed on separate mem-
brane preparations.
Table 1
Characteristics of the K2A-adrenoceptor^GiK fusion proteins
Fusion construct Kd [3H]RS
(nM)
Km GTP
(nM) basal
Km GTP (nM)
100 WM adrenaline
Turnover number
(min31)
Asp79Asn turnover number
as a percentage of Asp79
K2AGi1KC351I 0.55 þ 0.06 340 þ 13 449 þ 17 10.0 þ 0.7
K2AD79NGi1KC351I 0.45 þ 0.03 374 þ 33 306 þ 18 0.8 þ 0.2 8.3 þ 1.5
K2AGi2KC352I 0.40 þ 0.10 347 þ 19 291 þ 14 6.5 þ 0.3
K2AD79NGi2KC352I 0.70 þ 0.08 344 þ 16 359 þ 32 0.7 þ 0.3 11.7 þ 4.7
K2AGi3KC351I 0.47 þ 0.04 317 þ 17 389 þ 19 5.1 þ 0.5
K2AD79NGi3KC351I 0.50 þ 0.08 351 þ 40 360 þ 20 0.7 þ 0.2 14.0 þ 2.3
Saturation ligand binding studies were employed to measure Kd for [3H]RS-79948-197 at the various fusion proteins and to measure their ex-
pression levels. These varied between 1.7 and 14.5 pmol/mg membrane protein in individual transfections. Bmax values were used in association
with adrenaline (100 WM)-stimulated high a⁄nity GTPase activity at Vmax to calculate GTP turnover values for each construct. Data are pre-
sented as means þ S.E.M., n = 3 in each case. Adrenaline-stimulated turnover of GTP produced by the Asp79Asn K2A-adrenoceptor as a % of
that produced by the wild type receptor was not statistically di¡erent (Ps 0.05) between the three individual subtypes of Gi.
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adrenaline (100 WM) were then measured at a range of con-
centrations of GTP [16]. Extrapolation of such data to Vmax
indicated that adrenaline stimulated the maximal GTPase ac-
tivity of all the individual constructs. However, calculation of
adrenaline-stimulated turnover number demonstrated the
Arg351Gi1K-containing fusion protein to be least e¡ectively
activated by the agonist and the Ile351Gi1K-containing fusion
protein to be the most e¡ectively activated (Fig. 1).
Based on these observations an Asp79Asn K2A-adrenocep-
tor^Ile351Gi1K fusion protein was constructed and expressed
transiently in COS-7 cells. These mutations did not signi¢-
cantly alter the a⁄nity of binding of [3H]RS-79948-197 to
this or any of the other fusion proteins used (Table 1). Adre-
naline stimulation of the GTPase activity of this construct was
then compared directly with that of the wild type K2A-adre-
noceptor^Ile351Gi1K fusion protein (Fig. 2). Adrenaline was
able to cause the Asp79Asn K2A-adrenoceptor to produce
only 8.3 þ 1.5% of the GTPase turnover number of the fusion
protein-linked Gi1K compared to the wild type receptor (Table
1), even though the strategy used ensures that the ratio of
receptor to G protein must be maintained at a 1:1 stoichiom-
etry and that the physical proximity of receptor and G protein
must be the same in the two constructs. Moreover, the
Asp79Asn mutation did not alter the Km for GTP as substrate
(Table 1).
To ascertain whether there were di¡erential e¡ects of the
Asp79Asn K2A-adrenoceptor mutation on activation of the
other GiK subtypes, equivalent fusion constructs were gener-
ated between both the wild type and Asp79Asn K2A-adreno-
ceptor and each of Ile352Gi2K and Ile351Gi3K. Following tran-
sient expression of wild type and Asp79Asn K2A-
adrenoceptor^Ile352Gi2K, parallel [3H]RS-79948-197 ligand
binding and adrenaline (100 WM)-stimulated GTPase meas-
urements (Fig. 3a) indicated that the Asp79Asn substitution
equally severely restricted the activation of Gi2K. This muta-
tion reduced stimulation of the turnover of GTP by Gi2K to
11.7 þ 4.7% of that produced by the construct containing the
wild type receptor (Table 1). Equivalent experiments with fu-
sion constructs containing Ile351Gi3K (Fig. 3b) indicated that
the e¡ect of the Asp79Asn substitution of the K2A-adrenocep-
tor on adrenaline activation of this G protein was as dramatic
as that observed with the other G proteins (Table 1).
Previous co-transfection studies using the wild type and
Asp79Asn porcine K2A-adrenoceptor and Gi2K have indicated
that the receptor mutation substantially reduces the EC50 for
ligand activation of G protein without altering agonist bind-
ing a⁄nity [7]. To explore this in detail membranes expressing
either wild type or Asp79Asn K2A-adrenoceptor^Ile352Gi2K
fusion proteins were exposed to varying concentrations of
adrenaline (Fig. 4). Although the adrenaline stimulation of
Fig. 2. The e¡ects of an Asp79Asn mutation in the K2A-adrenocep-
tor on adrenaline-stimulated GTPase activity of K2A-adrenoceptor^
Gi1K fusion proteins. Wild type K2A-adrenoceptor^Ile351Gi1K
(circles) and Asp79Asn K2A-adrenoceptor^Ile351Gi1K (squares) fusion
proteins were expressed in COS-7 cells and membranes prepared.
Both basal (open symbols) and adrenaline (100 WM)-stimulated
(¢lled symbols) high a⁄nity GTPase activity was measured at a
range of GTP concentrations. Parallel measurement of fusion pro-
tein expression levels allowed quantitation of the e¡ect of the
Asp79Asn mutation (see Table 1).
Fig. 3. The e¡ects of an Asp79Asn mutation in the K2A-adrenoceptor on adrenaline-stimulated GTPase activity of K2A-adrenoceptor^Gi2K and
Gi3K fusion proteins. a: K2A-Adrenoceptor^Gi2K. b: K2A-adrenoceptor^Gi3K. Wild type K2A-adrenoceptor^Ile351Gi2K (a) or ^Ile351Gi3K (b)
(circles) and Asp79Asn K2A-adrenoceptor^Ile351Gi2K (a) or ^Ile351Gi3K (b) (squares) fusion proteins were expressed in COS-7 cells and mem-
branes prepared. Both basal (open symbols) and adrenaline (100 WM)-stimulated (¢lled symbols) high a⁄nity GTPase activity was measured at
a range of GTP concentrations. See Table 1 for quantitative analysis.
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Asp79Asn K2A-adrenoceptor^Ile352Gi2K was su⁄ciently small
to make estimates of EC50 imprecise, the measured value of
7.6U1037 M was only some 6-fold greater than for stimula-
tion of the wild type K2A-adrenoceptor^Ile352Gi2K fusion pro-
tein (1.3U1037 M) (Fig. 4).
4. Discussion
Mutation of an Asp residue, predicted to lie within trans-
membrane helix 2, which is the most highly conserved amino
acid in this transmembrane domain, has been performed for a
wide range of class 1 GPCRs. In general, mutation of this
residue to an Asn results in a decreased e⁄ciency of the
GPCR to generate a downstream signal and thus to interact
with relevant G proteins [22]. In the case of the K2A-adreno-
ceptor, although it is capable of interacting with all widely
expressed members of the pertussis toxin-sensitive Gi family
and of thus regulating a wide range of e¡ector endpoints, data
have appeared which could be interpreted as indicating that
the Asp79Asn mutation might selectively interfere with con-
tacts between the receptor and di¡erent G proteins. For ex-
ample, following expression in AtT20 pituitary cells, agonist
occupancy of the wild type GPCR allowed pertussis toxin-
sensitive inhibition of adenylyl cyclase and Ca2 currents
and stimulation of K current [2]. However, following expres-
sion of an Asp79Asn mutant of this receptor, agonist regula-
tion of the K current was lost but both of the other two
endpoints were maintained. Given that earlier antibody un-
coupling experiments had suggested key and separate roles for
Gi2 in mediating K2A-adrenoceptor inhibition of adenylyl cy-
clase in platelet membranes [23] and for Go in K2-adrenocep-
tor control of Ca2 channels in NG108-15 cells [24] then se-
lective uncoupling of G proteins by the Asp79Asn mutation is
clearly an attractive hypothesis. An alternative view is that the
mutation would non-selectively interfere with coupling to each
of the Gi-like G proteins as these are highly similar [7]. In
such a situation the apparent selective e¡ect on one measured
endpoint might re£ect di¡erent levels of expression of the
individual G proteins and/or the degree of ampli¢cation of
the initial receptor^G protein interaction required to modu-
late each endpoint. Neither of these issues has previously been
directly addressed.
In recent times we have made substantial use of a fusion
protein between the wild type porcine K2A-adrenoceptor and a
pertussis toxin-resistant form of Gi1K in which the acceptor
site for pertussis toxin-catalysed ADP-ribosylation (Cys351)
was converted to Gly [16,19,20]. This and other related
GPCR^G protein fusion proteins ([25,26], see [27] for review)
have a series of advantages for the quantitative analysis of
GPCR^G protein interactions and the e¡ects of point muta-
tions in either GPCR or G protein. These include the neces-
sity that the two elements of the fusion protein are present in
a 1:1 stoichiometry and that the proximity of the two ele-
ments is de¢ned and constrained by their physical linkage.
However, in many regards, the key issue is that the fusion
proteins function as agonist-activated GTPases and as such
can be used for enzyme kinetic analyses. Therefore, for the
current study we constructed fusion proteins between either
the wild type or Asp79Asn K2A-adrenoceptor and each of
Gi1K, Gi2K and Gi3K.
In initial experiments performed at a single concentration of
GTP (0.5 WM) the capacity of a receptor saturating concen-
tration of adrenaline to stimulate the GTPase activity of fu-
sion proteins in which either the wild type or Asp79Asn K2A-
adrenoceptor were linked to Gly351Gi1K was compared.
Although these experiments demonstrated a dramatic decrease
in e¡ect via the Asp79Asn K2A-adrenoceptor, the capacity of
adrenaline to stimulate this construct was su⁄ciently poor to
make quantitative analysis di⁄cult.
We have recently shown in co-transfection experiments that
the identity of the amino acid at residue 351 of Gi1K can
profoundly a¡ect the extent of receptor-mediated activation
[17]. As such, we constructed ¢ve further fusion proteins be-
tween the wild type K2A-adrenoceptor and forms of Gi1K with
di¡erent amino acids (Arg, Val, Phe and Ile) at residue 351.
Adrenaline-stimulated turnover numbers were calculated for
each using measurement of ligand-stimulated GTPase activity
at Vmax and of the levels of expression of each construct from
saturation 3H ligand binding studies. A three-fold range of
adrenaline-stimulated GTPase turnover numbers was re-
corded with the Ile351Gi1K-containing construct producing
the highest values. A fusion protein between the Asp79Asn
K2A-adrenoceptor and Ile351Gi1K allowed su⁄cient adrenaline
stimulation of GTPase activity that accurate estimates of the
e¡ect of the receptor mutation on G protein activation could
be recorded by calculation of turnover number at Vmax and
comparison with the values for the equivalent fusion protein
containing the wild type receptor sequence. Similar Ile351Gi3K-
and Ile352Gi2K-containing constructs were also much less ef-
fectively activated by adrenaline once the Asp79Asn K2A-adre-
noceptor was introduced into the fusion proteins.
These results indicate clearly and quantitatively that a
Asp79Asn mutation in the K2A-adrenoceptor interferes equiva-
lently with activation of the individual Gi subtypes. Based on
the results of Suprenant et al. [2], Limbird and colleagues
generated a transgenic mouse in which the wild type K2A-
Fig. 4. The e¡ect of an Asp79Asn mutation in the K2A-adrenoceptor
on the potency of adrenaline to stimulate Gi2K. Membranes as in
Fig. 3a expressing either the wild type K2A-adrenoceptor^Ile351Gi2K
(diamonds) or the Asp79Asn K2A-adrenoceptor^Ile351Gi2K (squares)
fusion proteins were exposed to varying concentrations of adrenaline
and high a⁄nity GTPase activity measured at 0.5 WM GTP.
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adrenoceptor gene sequence was replaced with one incorpo-
rating the Asp79Asn substitution [28] with the idea of under-
standing the role of speci¢c receptor^G protein interactions
and thus e¡ector systems in producing the wide ranging phys-
iological e¡ects attributed to the K2A-adrenoceptor by classi-
cal pharmacology and receptor knockout experiments (see [29]
for review). This approach was limited by the poor expression
of the Asp79Asn K2A-adrenoceptor compared to the wild type
[28] and in essence the transgenic animal behaved very much
as anticipated for a true K2A-adrenoceptor knock-out [30].
However, from the results provided herein one must assume
that if the expression levels of the mutant had been equivalent
to the wild type GPCR, the mouse model could not have
provided selective information on the roles and physiological
function of activation of Gi subtypes by the K2A-adrenocep-
tor.
The generation of fusion proteins between a GPCR and
closely related G protein K subunits has been integral to
this study as they have allowed direct quantitative analysis
in circumstances in which the expression ratio of each G pro-
tein to the GPCR was constant. Furthermore, analysis of
ligand regulation of G protein activation was extrapolated
to Vmax for each construct as estimated concentrations of
intracellular guanine nucleotides indicate this to be the likely
situation in vivo. This is the ¢rst direct quantitative demon-
stration of the e¡ect of a single point mutation in a GPCR on
signal transmission to closely related but individual G pro-
teins. Di¡erential e¡ects of a single GPCR mutation on di¡er-
ent e¡ector systems which are mediated by distinct but closely
related G proteins thus must result from di¡erential levels of
signal ampli¢cation required to produce the e¡ect or from
di¡erences in G protein expression levels or localisation.
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